跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
ELIQUIS 2,5 MG COMPRIMIDOS RECUBIERTOS CON PELICULA - CIMA-AEMPS Drug Approval Details
Approvals
/
CIMA-AEMPS
/
ELIQUIS 2,5 MG COMPRIMIDOS RECUBIERTOS CON PELICULA
Approved
STANDARD
ELIQUIS 2,5 MG COMPRIMIDOS RECUBIERTOS CON PELICULA
Bristol-Myers Squibb/Pfizer Eeig
🇪🇸 Spanish Agency of Medicines and Medical Devices
Approval Date
May 26, 2023
Approval ID
e2af3ccd3e0769f7
Company
Bristol-Myers Squibb/Pfizer Eeig
Type
Standard
Approval Details
Approval Id
e2af3ccd3e0769f7
Drug Cima Aemps Name
ELIQUIS 2,5 MG COMPRIMIDOS RECUBIERTOS CON PELICULA
Register Number
11691003IP
Holder Company Name
Bristol-Myers Squibb/Pfizer Eeig
Marketing Company Name
Melyfarma S.L.
Holder Company Detail Path
/organization/bristol-myers-squibb-pfizer-eeig
Authorization Date
2023-05-26
Dosage Form
COMPRIMIDO RECUBIERTO CON PELÍCULA
Dose
2,5 mg
Route Of Administration
VÍA ORAL
Prescription Type
Medicamento Sujeto A Prescripción Médica
Commercialized
Yes
Company Name
Bristol-Myers Squibb/Pfizer Eeig
Company Detail Path
/organization/bristol-myers-squibb-pfizer-eeig
Company Information
Pharmaceutical Company Name
BRISTOL-MYERS SQUIBB/PFIZER EEIG
Country Name
Ireland
City Name
dublin,country_ie
Address
Plaza 254 Blanchardstown Corporate Park 2
Active Ingredients
APIXABAN
2,5 mg
Approved
Quick Info
Agency
CIMA-AEMPS
Country
🇪🇸
Approval Date
May 26, 2023
Approval ID
e2af3ccd3e0769f7
Type
Standard
Back to CIMA-AEMPS Approvals
